Q4 2025

Filed Mar 31, 2026 · 10-K · 90 days after period end · 0001477932-26-001723

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue

$590.00K

derived+58,900.0% vs Q4 2024

Net Income

-$1.64M

derivedN/M vs Q4 2024

EPS, diluted—

Same quarter

Metric	Q4 2025derived from reported figures	Q4 2024derived from reported figures	Q4 2023derived from reported figures	Q4 2022derived from reported figures
Revenue	$590.00K	$1.00K	$32.00K	$0.00
Net Income	-$1.64M	-$652.00K	-$386.00K	-$4.01M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR